Table 2.
Response of HBeAg-positive patients to various doses and duration of PEG-IFN alfa-2a therapy analyzed according to endpoint
| Dose/Duration and endpoint | EOT | Time after end of treatment (years) | |||||
|---|---|---|---|---|---|---|---|
| 0.5 | 1 | 2 | 3 | 4 | 5 | ||
| 90 μg / 24 week | |||||||
| ALT normalization | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| HBeAg seroconversion | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Low HBV (<5 log copies/mL) | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| 180 μg / 24 week | |||||||
| ALT normalization | 0/4 | 0/4 | 0/4 | 1/4 | 0/3 | 0/3 | 0/3 |
| HBeAg seroconversion | 0/4 | 0/4 | 1/4 | 1/4 | 0/3 | 0/3 | 0/3 |
| Low HBV (<5 log copies/mL) | 2/4 | 0/4 | 1/4 | 2/4 | 0/3 | 0/3 | 0/3 |
| 90 μg/48 week | |||||||
| ALT normalization | 0/4 | 2/4 | 1/3 | 2/3 | 1/3 | 2/3 | 2/3 |
| HBeAg seroconversion | 1/4 | 1/4 | 1/3 | 2/3 | 2/3 | 2/3 | 2/3 |
| Low HBV (<5 log copies/mL) | 1/4 | 2/4 | 1/3 | 2/3 | 2/3 | 2/3 | 2/3 |
| 180 μg/48 week | |||||||
| ALT normalization | 1/5 | 3/5 | 2/5 | 2/5 | 2/4 | 1/4 | 1/4 |
| HBeAg seroconversion | 3/5 | 3/5 | 2/5 | 1/5 | 1/4 | 1/4 | 1/4 |
| Low HBV (<5 log copies/mL) | 4/5 | 1/5 | 1/5 | 1/5 | 1/4 | 1/4 | 1/4 |
EOT end of treatment